Growth Arrest-Specific 6 (GAS6) and its TAM receptor tyrosine kinase family (TYRO3, AXL, and MERTK) constitute a critical signaling axis implicated in tumor growth, metastasis, immune evasion, and drug resistance. As a key soluble ligand, GAS6 binds with high affinity to AXL, driving epithelial-to-mesenchymal transition (EMT) and suppressing anti-tumor immune responses. Developing therapeutic monoclonal antibodies, decoy receptors, and small molecule inhibitors targeting the GAS6-AXL pathway requires highly characterized, structurally intact recombinant proteins and cell-based validation systems.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for GAS6 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GAS6 Recombinant Protein (ECD-Fc / His-tag) High purity (>95%), Endotoxin <1.0 EU/μg. Sequence Verified. HEK293 expressed to preserve native post-translational modifications. |
View GAS6 Products |
| Gene Delivery | GAS6 Promise-ORF / Lentivirus Particles Full-length ORF lentivirus for stable cell line construction and overexpression validation. |
View GAS6 Products |
| Benchmark Ab | Anti-GAS6 Recombinant Biosimilar Sequence-derived positive control antibody for benchmark binding and neutralization studies. |
View GAS6 Products |
| Validator | GAS6 siRNA Set Target-specific knockdown pool for functional validation and specificity screening. |
View GAS6 Products |
| Related Target A | AXL Primary high-affinity receptor for GAS6. Crucial for establishing ligand-receptor binding and blocking assays. |
View AXL Products |
| Related Target B | MERTK Secondary TAM receptor. Essential for counter-screening to evaluate therapeutic selectivity and avoid off-target toxicity. |
View MERTK Products |
| Related Target C | TYRO3 TAM family member. Used in selectivity panels to profile broad-spectrum vs. selective TAM pathway inhibitors. |
View TYRO3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Gamma-Carboxylation Dependency | HEK293 mammalian expression system ensures native-like post-translational processing critical for Gla-domain conformation. |
| TAM Receptor Selectivity Profiling | Complete panel of high-purity AXL, TYRO3, and MERTK recombinant target proteins available for cross-reactivity screening. |
| Lack of Validated Controls | Sequence-verified clinical benchmark biosimilars included to establish reliable assay baselines. |
| Target Specificity & Off-Target Effects | Sequence-specific siRNA sets provided to confirm target-dependence in cell-based functional assays. |
Live GAS6 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of the GAS6-AXL axis is expanding rapidly beyond oncology into fibrotic diseases and autoimmune disorders. While small-molecule tyrosine kinase inhibitors (TKIs) targeting AXL often suffer from off-target cardiotoxicity due to multi-kinase inhibition, biologics targeting the ligand GAS6 offer superior selectivity. Decoy receptors (such as engineered AXL-Fc fusion proteins) and neutralizing monoclonal antibodies represent the dominant biologic modalities. The next wave of R&D focuses on combining GAS6 inhibitors with immune checkpoint blockers (anti-PD-1/PD-L1) to reverse myeloid-mediated immunosuppression in the tumor microenvironment.
Competitive Modality & Indication Snapshot
Connecting market trends to assay needs:
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Decoy Receptor (Trap) | Aravive (Batiraxcept), Lead Therapeutics | Ovarian Cancer, Renal Cell Carcinoma, Pancreatic Cancer | High-affinity binding assays (Requires high-purity GAS6 ECD-Fc for SPR/BLI kinetics) |
| Neutralizing mAb | Rigel Pharmaceuticals, Incyte | Solid Tumors, Acute Myeloid Leukemia (AML) | Ligand-receptor blocking assays (Requires stable GAS6 and AXL recombinant proteins) |
| Small Molecule TKI | BerGenBio (Bemcentinib), Exelixis | Non-Small Cell Lung Cancer (NSCLC), Triple-Negative Breast Cancer | Cell-based phosphorylation assays (Requires GAS6/AXL Lentivirus for stable cell line construction) |